Side-by-side · Research reference

5-Amino-1MQvsTesofensine

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft8/38 cited

BPhase 3Draft10/40 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

01Mechanism of Action

Parameter

5-Amino-1MQ

Tesofensine

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Feedback intact?

—

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

Tesofensine

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

0.25–0.5 mg / dayAstrup 2008

Frequency

Once daily, fasted

Once daily, morning

Lower / starter dose

50 mg / day

0.125 mg / day

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Phase 2b + ongoing Phase 3Astrup 2008

Duration

8–12 weeks per cycle

24 weeks per studied cycle

Form

Oral capsule

Timing

Morning fasted preferred

Morning to avoid sleep disruption

Half-life

Hours (estimated; no human PK published)

~9 days (very long)

04Side Effects & Safety

Parameter

5-Amino-1MQ

Tesofensine

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

Contraindicated

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Heart rate / BP

—

Dose-dependent ↑ HR + BPAstrup 2008

Insomnia

—

Dose-related; mitigate with morning timing

Dry mouth

—

Common

Nausea

—

Common

Mood changes

—

Anxiety / agitation possible

Cardiovascular events

—

Phase 3 trial monitoring; not yet FDA-cleared

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

05Administration Protocol

Parameter

5-Amino-1MQ

Tesofensine

1. Form

Oral capsule. No injection.

Oral capsule (investigational; not commercial).

2. Administration

Take with water, fasted preferred.

Swallow whole with water, morning only.

3. Timing

Morning fasted.

Morning to mitigate insomnia. Do not dose evening.

4. Storage

Room temp ≤25 °C, dry place.

5. Caveat

Monitor B-vitamin status with chronic use.

Monitor BP + HR + mood. Avoid stimulants + MAOIs.